Expression of the p53 family in lung cancer

Anticancer Research

Volumn 26, Issue 3 A, 2006, Pages 1785-1790

  Uramoto, Hidetaka ^a   Sugio, Kenji ^a   Oyama, Tsunehiro ^a   Nakata, Shoji ^a   Ono, Kenji ^a   Nozoe, Tadahiro ^a   Yasumoto, Kosei ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Np63; Np73; Immunohistochemistry; Lung cancer; p53; Prognostic factor

Indexed keywords

PROTEIN P53; PROTEIN P63; PROTEIN P73;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 33745595067     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics, CA. Cancer J Clin 48: 6-29, 1998.
2. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111: 1710-1717, 1997.
3. Strauss GM, Kwiatkowski DJ, Harpole DH, Lynch TJ, Skarin AT and Sugarbaker DJ: Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. J Clin Oncol 13: 1265-1279, 1995.
4. Pao W and Miller VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 10: 2556-2568, 2005.
5. Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature 408: 307-310, 2000.
6. Irwin MS and Kaelin WG: p53 family update: p73 and p63 develop their own identities. Cell Growth Differ 12: 337-349, 2001.
7. Moll UM, Erster S and Zaika A: p53, p63 and p73 - solos, alliances and feuds among family members. Biochim Biophys Acta 1552: 47-59, 2001.
8. Melino G, De Laurenzi V and Vousden KH: p73: friend or foe in tumorigenesis. Nat Rev Cancer 2: 605-615, 2002.
9. Stiewe T and Putzer BM: p73 in apoptosis. Apoptosis 6: 447-452, 2001.
10. Uramoto H, Osaki T, Inoue M, Taga S, Takenoyama M, Hanagiri T, Yoshino I, Nakanishi R, Ichiyoshi Y and Yasumoto K: Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patients. Eur J Cancer 35: 1462-1465, 1999.
11. Dobashi K, Sugio K, Osaki T, Oka T and Yasumoto K: Micrometastatic p53-positive cells in the lymph nodes of non-small-cell lung cancer: prognostic significance. J Thorac Cardiovasc Surg 114: 339-346, 1997.
12. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Morita M, Funa K and Yasumoto K: Expression of deltaNp73 predicts poor prognosis in lung cancer. Clin Cancer Res 10: 6905-6911, 2004.
13. Iwata T, Uramoto H, Sugio K, Fujino Y, Oyama T, Nakata S, Ono K, Morita M and Yasumoto K: Absence of prognostic significance of deltaNp63 immunoreactivity in lung cancer. Lung Cancer 50: 67-73, 2005.
14. Koga F, Kawakami S, Fujii Y, Saito K, Ohtsuka Y, Iwai A, Ando N, Takizawa T, Kageyama Y and Kihara K: Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res 9: 5501-5507, 2003.
15. Kaplan E and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
16. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J and Smith PG: Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Br J Cancer 35: 1-39, 1977.
17. Cox D: Regression models and life tables. J R Stat Soc 34: 187-220, 1972.
18. Oren M: Lonely no more: p53 finds its kin in a tumor suppressor haven. Cell 90: 829-832, 1997.
19. Weill D, Mack M, Roth J, Swisher S, Proksch S, Merritt J and Nemunaitis J: Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection. Chest 118: 966-970, 2000.
20. Polyak K, Waldman T, He TC, Kinzler KW and Vogelstein B: Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 10: 1945-1952, 1996.
21. Rodicker F and Putzer BM: p73 is effective in p53-null pancreatic cancer cells resistant to wild-type TP53 gene replacement. Cancer Res 63: 2737-2741, 2003.
22. Melino G, Lu X, Gasco M, Crook T and Knight RA: Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci 28: 663-670, 2003.
23. Uramoto H, Izumi H, Ise T, Tada M, Uchiumi T, Kuwano M, Yasumoto K, Funa K and Kohno K: p73 interacts with c-Myc to regulate Y-box-binding protein-1 expression. J Biol Chem 277: 31694-31702, 2002.
24. Uramoto H, Izumi H, Nagatani G, Ohmori H, Nagasue N, Ise T, Yoshida T, Yasumoto K and Kohno K: Physical interaction of tumour suppressor p53/p73 with CCAAT-binding transcription factor 2 (CTF2) and differential regulation of human high-mobility group 1 (HMG1) gene expression. Biochem J 371: 301-310, 2003.
25. Hackzell A, Uramoto H, Izumi H, Kohno K and Funa K: p73 independent of c-Myc represses transcription of platelet-derived growth factor beta-receptor through interaction with NF-Y. J Biol Chem 277: 39769-39676, 2002.
26. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F and Caput D: p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404: 99-103, 2000.
27. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR and Bradley A: p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398: 708-713, 1999.
28. Zaika AI, Kovalev S, Marchenko ND and Moll UM: Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res 59: 3257-3263, 1999.
29. Frasca F, Vella V, Aloisi A, Mandarino A, Mazzon E, Vigneri R and Vigneri P: p73 tumor-suppressor activity is impaired in human thyroid cancer. Cancer Res 63: 5829-5837, 2003.
30. Casciano I, Mazzocco K, Boni L, Pagnan G, Banelli B, Allemanni G, Ponzoni M, Tonini GP and Romani M: Expression of deltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 9: 246-251, 2002.
31. Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y and Yasumoto K: Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 115: 1007-1014, 1998.
32. Shibahara K, Sugio K, Osaki T, Uchiumi T, Maehara Y, Kohno K, Yasumoto K, Sugimachi K and Kuwano M: Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 7: 3151-3155, 2001.
33. Yoshimatsu T, Uramoto H, Oyama T, Yashima Y, Gu C, Morita M, Sugio K, Kohno K and Yasumoto K: Y-box-binding protein-1 expression is not correlated with p53 expression but with proliferating cell nuclear antigen expression in non-small cell lung cancer. Anticancer Res 25: 3437-3443, 2005.
34. Gu CD, Osaki T, Oyama T, Inoue M, Kodate M, Dobashi K, Oka T and Yasumoto K: Detection of micrometastatic tumor cells in pNO lymph nodes of patients with completely resected non small cell lung cancer: impact on recurrence and survival. Ann Surg 235: 133-139, 2002.
35. Osaki T, Oyama T, Gu CD, Yamashita T, So T, Takenoyama M, Sugio K and Yasumoto K: Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage I non-small-cell lung cancer. J Clin Oncol 20: 2930-2936, 2002.
36. Yasumoto K, Osaki T, Watanabe Y, Kato H and Yoshimura T: Prognostic value of cytokeratin-positive cells in the bone marrow and lymph nodes of patients with resected non small cell lung cancer: a multicenter prospective study. Ann Thorac Surg 76: 194-201, 2003.
37. Osaki T, Mitsudomi T, Oyama T, Nakanishi R and Yasumoto K: Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma. Chest 108: 157-162, 1995.
38. Mitsudomi T, Oyama T, Nishida K, Ogami A, Osaki T, Sugio K, Yasumoto K, Sugimachi K and Gazdar AF: Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication. Clin Cancer Res 2: 1185-1189, 1996.
39. Sugio K, Ishida T, Yokoyama H, Inoue T, Sugimachi K and Sasazuki T: Ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 52: 2903-2906, 1992.
40. Sugio K, Inoue T, Inoue K, Yaita H, Inuzuka S, Ishida T and Sugimachi K: Different site mutation of the K-ras gene in a patient with metachronous double lung cancers. Anticancer Res 13: 2469-2471, 1993.
41. Taga S, Osaki T, Ohgami A, Imoto H and Yasumoto K: Prognostic impact of telomerase activity in non-small cell lung cancers. Ann Surg 230: 715-720, 1999.
42. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Yoshimastu T, Morita M and Yasumoto K: Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance. Lung Cancer 49: 55-62, 2005.